title: Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir.
abstract: OBJECTIVE
  Cidofovir is an acyclic nucleotide phosphonate antiviral medication that has been used intralesionally for the treatment of severe respiratory papillomatosis (RRP) in pediatric patients. The long-term efficacy of this medication was assessed in 11 children with severe RRP who previously required operative debulking every 2 to 6 weeks to maintain airway patency.
  
  
  METHODS
  Clinical case series.
  
  
  RESULTS
  Ten of these children have completed therapy. Five are disease free over a mean follow-up period of 51.6 months. Five other patients with active RRP decreased their mean severity scores from 17.8 (range 11-26) to 4.0 (range 2-6) and no longer require cidofovir. One patient continues to receive cidofovir for recurrent disease after an initial favorable response. Throughout the 6-year observational period, no patients demonstrated any adverse effects, laboratory abnormalities, or evidence of carcinogenesis.
  
  
  CONCLUSIONS
  Intralesional cidofovir is a useful adjunct for managing children with tenuous airways caused by previously uncontrolled papilloma.
authors.affiliation: Children's Hospital and Health Center, San Diego, CA 92123, USA. spransky@chsd.org
authors.forename: Seth M
authors.initials: SM
authors.lastname: Pransky
authors.forename: James T
authors.initials: JT
authors.lastname: Albright
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Magit
mesh_terms: D000402:Airway Obstruction / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D000077404:Cidofovir; D003131:Combined Modality Therapy; D003596:Cytosine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D010212:Papilloma / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir